Download a .PDF copy here
Context:
This report is prepared in advance of the National Screening Committee (NSC) meeting on prostate cancer screening, to be chaired by Professor Mike Richards on November 27, 2025.
It highlights the public health imperative of optimizing vitamin D status as a complementary strategy to targeted PSA screening for high-risk men (e.g., Black men, those with family history, or BRCA mutations).
Drawing on the Scientists’ Call to D*action (initiated in 2008 and updated in 2024 by GrassrootsHealth), it focuses on the benefits of serum 25-hydroxyvitamin D [25(OH)D] levels of 100-150 nmol/L (equivalent to 40-60 ng/mL) for men, with emphasis on prostate cancer prevention, progression, and mortality reduction.
Executive Summary
Vitamin D deficiency affects 40-75% of the global population, including a significant proportion of UK men, exacerbating risks for chronic diseases.
Since 2008, leading scientists have advocated for public health targets for
25(OH)D of 100-150 nmol/L to suppress parathyroid hormone, optimize gene regulation (affecting ~3,000 genes), and reduce disease incidence by 20-50%.
For men, this target offers multifaceted benefits: reduced prostate cancer risk and mortality (particularly for aggressive forms), enhanced immune function to combat infections, improved bone and muscle health to prevent falls/fractures, and lower overall mortality from cardiovascular and metabolic diseases.
Implementing routine testing and supplementation could amplify the impact of NSC’s targeted screening, potentially saving thousands of lives annually while addressing disparities in high-risk groups like Black men, who often face compounded vitamin D deficiency due to skin pigmentation and limited sun exposure.
Very Important Note:
When reading scientific reports about Deficiency of Vitamin D, always check what definition of Deficiency is being used – as this can change some results
USA always sets Deficiency at 50nmol/L
UK sets Deficiency at 25-30 nmol/L
- 25 nmol/L: Used in some NHS trust guidelines (e.g., North Bristol or Royal United Hospitals Bath) as a stricter cutoff for severe deficiency requiring high-dose loading therapy. However, it’s not the standard NHS-wide definition for deficiency.
- 30 nmol/L: This is the primary NHS threshold for deficiency.
- 50 nmol/L: Marks the boundary for adequacy; levels below this may warrant monitoring but aren’t classified as deficiency.
Background: The Scientists’ Call to D*action
In 2008, GrassrootsHealth convened 40 vitamin D experts to address the global deficiency epidemic, critiquing inadequate intake recommendations from bodies like the Institute of Medicine (IOM). The inaugural Call to D*action urged achieving 25(OH)D 100-150 nmol/L through supplementation (up to 10,000 IU/day safely), fortified foods, or sun exposure.
The 2024 update, endorsed by 48 senior researchers, counters the Endocrine Society’s conservative guidelines, emphasizing evidence from over 15 years of trials showing no toxicity for 25(OH)D below 312 nmol/L and broad health gains.
https://www.grassrootshealth.net/scientists-call-daction-public-health-2024/
This target aligns with ancestral levels in equatorial populations and optimizes outcomes for skeletal and extra-skeletal conditions, including cancers.
General Health Benefits for Men of 25(OH)D at 100-150 nmol/L
Achieving 100-150nmol/L yields dose-dependent benefits, supported by randomized trials and meta-analyses. Key advantages include:
|
Benefit Category |
Specific Outcomes | Evidence Summary |
| Immune Function | Reduced acute infections (e.g., influenza, COVID-19 hospitalization ↓37%); prevention of autoimmune diseases (e.g., MS, Type 1 diabetes ↓22%); chronic infection control (e.g., TB). | VITAL trial reanalysis; Holick et al. (2019) gene regulation study showing 1,289 genes modulated at higher doses.
grassrootshealth.net |
| Bone & Muscle Health | Optimal parathyroid suppression; ↓ falls/fractures by 20-30%; improved lower-extremity function and BMD. | Thresholds ≥75 nmol/L for benefits, peaking at 90-100 nmol/L; MrOS cohort (older men).
pubmed.ncbi.nlm.nih.gov +1 |
| Cardiovascular & Metabolic | ↓ Hypertension/heart failure; prediabetes-to-diabetes transition ↓; metabolic syndrome risk ↓. | D2d trial (≥100 nmol/L protective); community programs showing BP benefits.
grassrootshealth.net |
| Overall Mortality | All-cause mortality ↓15-20%; cancer mortality ↓ (e.g., VITAL reanalysis). | Dose-response meta-analyses; levels <50 nmol/L linked to adverse effects.
pubmed.ncbi.nlm.nih.gov |
These benefits are achievable without risk: historical high-dose trials (1930s-1940s) and modern protocols confirm safety up to 55,000 IU/day for short periods, with no hypercalcemia below 400 nmol/L.
Prostate Cancer-Specific Benefits for Men
Prostate cancer, the UK’s most common cancer (55,300 cases/year), disproportionately affects high-risk groups targeted by NSC.
Vitamin D’s active form (1,25(OH)2D) exerts anti-proliferative, pro-differentiating effects on prostate cells via receptors and local metabolism enzymes.
https://pubmed.ncbi.nlm.nih.gov/15225833/
USA Deficiency (<50 nmol/L) is hypothesized to drive aggressive disease, especially in Black men (2x mortality risk) and those with BRCA mutations, compounded by low sun exposure and darker skin reducing synthesis.
When Vitamin D blood levels are equalised between people with light and dark skin, then health outcomes – including prostate cancer risk and mortality – are remarkably similar.
-
Risk Reduction:
Deficiency doubles all-cancer risk (OR 2.0 for <30 nmol/L vs. ≥75 nmol/L).
Meta-analyses link low 25(OH)D to increased incidence
https://www.mdpi.com/2072-6643/11/10/2295
https://pubmed.ncbi.nlm.nih.gov/24838848/
GrassrootsHealth studies suggest 100-150 nmol/L prevents and reverses early lesions; a 1-year trial with 4,000 IU/day achieved mean 150 nmol/L, correlating with tumour regression in some men.
https://pubmed.ncbi.nlm.nih.gov/22508710/
-
Aggressive Disease & Mortality:
Higher levels reduce Gleason 8-10 risk (HR 0.96 per 10 nmol/L ↑) and post-diagnosis mortality (dose-response meta: HR 0.88 for highest vs. lowest quartile).
https://pubmed.ncbi.nlm.nih.gov/25085836/
In aggressive PCa, 25(OH)D >80 nmol/L halves mortality vs. <50 nmol/L (HR 0.42).
https://pubmed.ncbi.nlm.nih.gov/26518197/
DaPCaR cohort: Deficiency increases PCa-specific mortality 2.37-fold.
https://pubmed.ncbi.nlm.nih.gov/32385370/
- High-Risk Groups: Black men and BRCA carriers (3x aggressive risk) benefit most; trials show annual PSA detects more in BRCA+ men at ≥100 nmol/L.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6240137/
Genetic variants (e.g., DBP) modify effects, with high DBP + low vitamin D ↑ risk, underscoring testing.
https://pubmed.ncbi.nlm.nih.gov/23180681/
Note: Some studies show U-shaped risks (modest increase of low-grade cancers at very high levels), but benefits for aggressive disease dominate; overall, deficiency is the greater threat.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6330070/
Recommendations for NSC Integration
- Advocate Testing: Include 25(OH)D screening in targeted programs for
1.375 million high-risk men (Black aged 45-69 + family history aged 50-69), as levels inform PSA reliability and guide supplementation.
- Public Health Campaign: Promote 100-150 nmol/L via NHS guidelines, aligning with Transform trial’s multi-modal approach (PSA + MRI + genetics).
- Equity Focus: Address data gaps in ethnicity/family history while piloting vitamin D interventions for Black/BRCA+ men to reduce disparities.
- Next Steps: Post-consultation, model cost-savings: Eradicating deficiency could reduce PCa deaths by 20% (2,440/year), mirroring breast/bowel screening efficiencies.
This strategy empowers men proactively, balancing “head vs. heart” by preventing harm through evidence-based optimization.
